Expression of the EphA1 protein is associated with Fuhrman nuclear grade in clear cell renal cell carcinomas.
Aberrant expression of receptor tyrosine kinase EphA1 in malignant tissues has been reported. However, the expression profile of EphA1 in renal cell carcinoma (RCC) and its association with clinicopathological parameters remain unknown. The aim of this study was to determine the cancerous value of the EphA1 protein expression in patients with renal cell carcinomas. This study included 144 patients with clear cell RCC (ccRCC), 18 patients with chromophobe RCC and 6 patients with papillary RCC. The EphA1 protein was detected in RCC tissue samples by an immunohistochemical staining with a specific polycolonal antibody. The correlation of the expression of the EphA1 protein with clinicopathological parameters was evaluated. High level of the expression of EphA1 was observed in all normal renal tubes. The EphA1 protein was negatively or weakly expressed in 93 out of 144 ccRCC (64.6%) and positively expressed in 51 out of 144 ccRCC (35.4%). The high level expression of the EphA1 protein was significantly associated with younger patients (P<0.001), sex (P=0.016) and lower nuclear grade (P<0.001). No significant relation between the expression of EphA1 and tumor diameter was found (P=0.316). Positive expression of EphA1 was observed in all samples of chromophobe RCC and papillary RCC. Our data indicated that the EphA1 protein may be a new marker for the prognosis of ccRCC.
Department of Urology, Nantong Tumor Hospital Nantong 226361, Jiangsu, China.
Xiaolin
X
Wang
Department of Pathology, Nantong Tumor Hospital Nantong 226361, Jiangsu, China.
Yushan
Y
Liu
Department of Urology, Nantong Tumor Hospital Nantong 226361, Jiangsu, China.
Guangxin
G
Cao
Department of Urology, Nantong Tumor Hospital Nantong 226361, Jiangsu, China.
Xueliang
X
Zhang
Department of Urology, Nantong Tumor Hospital Nantong 226361, Jiangsu, China.
Haifei
H
Xu
Department of Oncology, Second Affiliated Hospital, Southeast University Nanjing 210003, Jiangsu, China.
Hanfeng
H
Xu
Department of Pathology, Jinling Hospital Nanjing 210002, China.
Jiandong
J
Wang
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000201:enzymology* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000201:enzymology* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009392:Nephrectomy; D011237:Predictive Value of Tests; D036082:Receptor, EphA1 / Q000032:analysis*
D014408:Biomarkers, Tumor; D036082:Receptor, EphA1
EphA1; Fuhrman nuclear grade; clear cell renal cell carcinoma; receptor tyrosine kinase